Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 426

1.

Extended delivery of vaccines to the skin improves immune responses.

Joyce JC, Sella HE, Jost H, Mistilis MJ, Esser ES, Pradhan P, Toy R, Collins ML, Rota PA, Roy K, Skountzou I, Compans RW, Oberste MS, Weldon WC, Norman JJ, Prausnitz MR.

J Control Release. 2019 May 6;304:135-145. doi: 10.1016/j.jconrel.2019.05.006. [Epub ahead of print] French.

PMID:
31071375
2.

Co-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection.

Kim MC, Kim KH, Lee JW, Lee YN, Choi HJ, Jung YJ, Kim YJ, Compans RW, Prausnitz MR, Kang SM.

Pharmaceutics. 2019 Apr 18;11(4). pii: E188. doi: 10.3390/pharmaceutics11040188.

3.

Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Deng L, Chang TZ, Wang Y, Li S, Wang S, Matsuyama S, Yu G, Compans RW, Li JD, Prausnitz MR, Champion JA, Wang BZ.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7758-E7767. doi: 10.1073/pnas.1805713115. Epub 2018 Jul 31.

4.

Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge.

Liu Y, Ye L, Lin F, Gomaa Y, Flyer D, Carrion R Jr, Patterson JL, Prausnitz MR, Smith G, Glenn G, Wu H, Compans RW, Yang C.

Sci Rep. 2018 Jul 25;8(1):11193. doi: 10.1038/s41598-018-29135-w.

5.

Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge.

Liu Y, Ye L, Lin F, Gomaa Y, Flyer D, Carrion R Jr, Patterson JL, Prausnitz MR, Smith G, Glenn G, Wu H, Compans RW, Yang C.

J Infect Dis. 2018 Nov 22;218(suppl_5):S545-S552. doi: 10.1093/infdis/jiy267.

PMID:
29893888
6.

NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, Wilson PC, Compans RW, Skountzou I, Monto AS.

MBio. 2018 Apr 3;9(2). pii: e02332-17. doi: 10.1128/mBio.02332-17. Review.

7.

Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.

Littauer EQ, Mills LK, Brock N, Esser ES, Romanyuk A, Pulit-Penaloza JA, Vassilieva EV, Beaver JT, Antao O, Krammer F, Compans RW, Prausnitz MR, Skountzou I.

J Control Release. 2018 Apr 28;276:1-16. doi: 10.1016/j.jconrel.2018.02.033. Epub 2018 Feb 26.

8.

Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses.

Deng L, Mohan T, Chang TZ, Gonzalez GX, Wang Y, Kwon YM, Kang SM, Compans RW, Champion JA, Wang BZ.

Nat Commun. 2018 Jan 24;9(1):359. doi: 10.1038/s41467-017-02725-4.

9.

Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine.

Vassilieva EV, Wang S, Li S, Prausnitz MR, Compans RW.

Sci Rep. 2017 Dec 19;7(1):17855. doi: 10.1038/s41598-017-18140-0.

10.

Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins.

Gangadhara S, Kwon YM, Jeeva S, Quan FS, Wang B, Moss B, Compans RW, Amara RR, Jabbar MA, Kang SM.

Vaccines (Basel). 2017 Dec 19;5(4). pii: E52. doi: 10.3390/vaccines5040052.

11.

H1N1 influenza virus infection results in adverse pregnancy outcomes by disrupting tissue-specific hormonal regulation.

Littauer EQ, Esser ES, Antao OQ, Vassilieva EV, Compans RW, Skountzou I.

PLoS Pathog. 2017 Nov 27;13(11):e1006757. doi: 10.1371/journal.ppat.1006757. eCollection 2017 Nov.

12.

Microneedle patch delivery of influenza vaccine during pregnancy enhances maternal immune responses promoting survival and long-lasting passive immunity to offspring.

Esser ES, Pulit-Penaloza JA, Kalluri H, McAllister D, Vassilieva EV, Littauer EQ, Lelutiu N, Prausnitz MR, Compans RW, Skountzou I.

Sci Rep. 2017 Jul 18;7(1):5705. doi: 10.1038/s41598-017-05940-7.

13.

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.

Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, Kabbani S, Lai L, Vassilieva EV, Skountzou I, Compans RW, Mulligan MJ, Prausnitz MR; TIV-MNP 2015 Study Group.

Lancet. 2017 Aug 12;390(10095):649-658. doi: 10.1016/S0140-6736(17)30575-5. Epub 2017 Jun 27.

14.

Ebola Vaccination Using a DNA Vaccine Coated on PLGA-PLL/γPGA Nanoparticles Administered Using a Microneedle Patch.

Yang HW, Ye L, Guo XD, Yang C, Compans RW, Prausnitz MR.

Adv Healthc Mater. 2017 Jan;6(1). doi: 10.1002/adhm.201600750. Epub 2016 Nov 7.

PMID:
28075069
15.

Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses.

Mohan T, Berman Z, Luo Y, Wang C, Wang S, Compans RW, Wang BZ.

Sci Rep. 2017 Jan 9;7:40226. doi: 10.1038/srep40226.

16.

Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.

Wang L, Chang TZ, He Y, Kim JR, Wang S, Mohan T, Berman Z, Tompkins SM, Tripp RA, Compans RW, Champion JA, Wang BZ.

Nanomedicine. 2017 Jan;13(1):253-262. doi: 10.1016/j.nano.2016.09.001. Epub 2016 Sep 10.

17.

"Cytoplasmic domain effects on exposure of co-receptor-binding sites of HIV-1 Env".

Vzorov AN, Compans RW.

Arch Virol. 2016 Nov;161(11):3011-8. doi: 10.1007/s00705-016-2998-1. Epub 2016 Aug 3.

18.

[VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties].

Vzorov AN, Compans RW.

Mol Biol (Mosk). 2016 May-Jun;50(3):406-15. doi: 10.7868/S0026898416030113. Review. Russian.

19.

Tetanus vaccination with a dissolving microneedle patch confers protective immune responses in pregnancy.

Esser ES, Romanyuk A, Vassilieva EV, Jacob J, Prausnitz MR, Compans RW, Skountzou I.

J Control Release. 2016 Aug 28;236:47-56. doi: 10.1016/j.jconrel.2016.06.026. Epub 2016 Jun 18.

PMID:
27327766
20.

Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.

Mohan T, Kim J, Berman Z, Wang S, Compans RW, Wang BZ.

J Control Release. 2016 Jul 10;233:208-19. doi: 10.1016/j.jconrel.2016.05.021. Epub 2016 May 10.

21.

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.

Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA.

Sci Rep. 2016 Apr 25;6:24897. doi: 10.1038/srep24897.

22.

Long-term stability of influenza vaccine in a dissolving microneedle patch.

Mistilis MJ, Joyce JC, Esser ES, Skountzou I, Compans RW, Bommarius AS, Prausnitz MR.

Drug Deliv Transl Res. 2017 Apr;7(2):195-205. doi: 10.1007/s13346-016-0282-2.

23.

Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines.

Vzorov AN, Wang L, Chen J, Wang BZ, Compans RW.

Virology. 2016 Feb;489:141-50. doi: 10.1016/j.virol.2015.09.015. Epub 2016 Jan 4.

24.

Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches.

Chu LY, Ye L, Dong K, Compans RW, Yang C, Prausnitz MR.

Pharm Res. 2016 Apr;33(4):868-78. doi: 10.1007/s11095-015-1833-9. Epub 2015 Dec 1.

25.
26.

Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles.

Choi HJ, Song JM, Bondy BJ, Compans RW, Kang SM, Prausnitz MR.

PLoS One. 2015 Jul 31;10(7):e0134431. doi: 10.1371/journal.pone.0134431. eCollection 2015.

27.

Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor.

Pulit-Penaloza JA, Sapkota B, Stein Esser E, Compans RW, Pollack BP, Skountzou I.

Sci Rep. 2015 Jul 31;5:12321. doi: 10.1038/srep12321.

28.

Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.

Feng H, Zhang H, Deng J, Wang L, He Y, Wang S, Seyedtabaei R, Wang Q, Liu L, Galipeau J, Compans RW, Wang BZ.

Sci Rep. 2015 Jul 7;5:11856. doi: 10.1038/srep11856.

29.

Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.

Vassilieva EV, Kalluri H, McAllister D, Taherbhai MT, Esser ES, Pewin WP, Pulit-Penaloza JA, Prausnitz MR, Compans RW, Skountzou I.

Drug Deliv Transl Res. 2015 Aug;5(4):360-71. doi: 10.1007/s13346-015-0228-0.

30.

Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.

Li W, Ye L, Carrion R Jr, Mohan GS, Nunneley J, Staples H, Ticer A, Patterson JL, Compans RW, Yang C.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S398-403. doi: 10.1093/infdis/jiv186. Epub 2015 Apr 14.

31.

Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.

Patel JM, Kim MC, Vartabedian VF, Lee YN, He S, Song JM, Choi HJ, Yamanaka S, Amaram N, Lukacher A, Montemagno CD, Compans RW, Kang SM, Selvaraj P.

Nanomedicine. 2015 Jul;11(5):1097-107. doi: 10.1016/j.nano.2015.02.008. Epub 2015 Mar 6.

32.

Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts.

Koutsonanos DG, Esser ES, McMaster SR, Kalluri P, Lee JW, Prausnitz MR, Skountzou I, Denning TL, Kohlmeier JE, Compans RW.

Vaccine. 2015 Sep 8;33(37):4675-82. doi: 10.1016/j.vaccine.2015.01.086. Epub 2015 Mar 3.

33.

Memory T cells generated by prior exposure to influenza cross react with the novel H7N9 influenza virus and confer protective heterosubtypic immunity.

McMaster SR, Gabbard JD, Koutsonanos DG, Compans RW, Tripp RA, Tompkins SM, Kohlmeier JE.

PLoS One. 2015 Feb 11;10(2):e0115725. doi: 10.1371/journal.pone.0115725. eCollection 2015.

34.

Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Mohan GS, Ye L, Li W, Monteiro A, Lin X, Sapkota B, Pollack BP, Compans RW, Yang C.

J Virol. 2015 Jan 15;89(2):1205-17. doi: 10.1128/JVI.01810-14. Epub 2014 Nov 12.

35.

Protocatechuic acid, a novel active substance against avian influenza virus H9N2 infection.

Ou C, Shi N, Yang Q, Zhang Y, Wu Z, Wang B, Compans RW, He C.

PLoS One. 2014 Oct 22;9(10):e111004. doi: 10.1371/journal.pone.0111004. eCollection 2014.

36.

Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.

Lee S, Quan FS, Kwon Y, Sakamoto K, Kang SM, Compans RW, Moore ML.

Antiviral Res. 2014 Nov;111:129-35. doi: 10.1016/j.antiviral.2014.09.005. Epub 2014 Sep 18.

37.

A protective role of murine langerin⁺ cells in immune responses to cutaneous vaccination with microneedle patches.

Pulit-Penaloza JA, Esser ES, Vassilieva EV, Lee JW, Taherbhai MT, Pollack BP, Prausnitz MR, Compans RW, Skountzou I.

Sci Rep. 2014 Aug 18;4:6094. doi: 10.1038/srep06094.

38.

Skin immunization with influenza vaccines.

Skountzou I, Compans RW.

Curr Top Microbiol Immunol. 2015;386:343-69. doi: 10.1007/82_2014_407. Review.

39.

Universal influenza vaccines, a dream to be realized soon.

Zhang H, Wang L, Compans RW, Wang BZ.

Viruses. 2014 Apr 29;6(5):1974-91. doi: 10.3390/v6051974. Review.

40.

Distinct B-cell populations contribute to vaccine antigen-specific antibody production in a transgenic mouse model.

O E, Ko EJ, Kim MC, Lee YT, Song JM, Kwon YM, Compans RW, Kang SM.

Immunology. 2014 Aug;142(4):624-35. doi: 10.1111/imm.12287.

41.

Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.

Kim MC, Lee YN, Ko EJ, Lee JS, Kwon YM, Hwang HS, Song JM, Song BM, Lee YJ, Choi JG, Kang HM, Quan FS, Compans RW, Kang SM.

Mol Ther. 2014 Jul;22(7):1364-1374. doi: 10.1038/mt.2014.33. Epub 2014 Mar 4.

42.

Cutaneous immunization: an evolving paradigm in influenza vaccines.

Gill HS, Kang SM, Quan FS, Compans RW.

Expert Opin Drug Deliv. 2014 Apr;11(4):615-27. doi: 10.1517/17425247.2014.885947. Epub 2014 Feb 12. Review.

43.

Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.

Wang BZ, Gill HS, He C, Ou C, Wang L, Wang YC, Feng H, Zhang H, Prausnitz MR, Compans RW.

J Control Release. 2014 Mar 28;178:1-7. doi: 10.1016/j.jconrel.2014.01.002. Epub 2014 Jan 11.

44.

Mucosal adjuvants for influenza virus-like particle vaccine.

Quan FS, Ko EJ, Kwon YM, Joo KH, Compans RW, Kang SM.

Viral Immunol. 2013 Dec;26(6):385-95. doi: 10.1089/vim.2013.0013. Epub 2013 Nov 16.

45.

Closely related influenza viruses induce contrasting respiratory tract immunopathology.

Le VL, Courtney CL, Steel J, Compans RW.

PLoS One. 2013 Sep 26;8(9):e76708. doi: 10.1371/journal.pone.0076708. eCollection 2013.

46.

Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.

Wang L, Hess A, Chang TZ, Wang YC, Champion JA, Compans RW, Wang BZ.

Nanomedicine. 2014 Feb;10(2):473-82. doi: 10.1016/j.nano.2013.08.005. Epub 2013 Aug 27.

47.

Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice.

Wang L, Wang YC, Feng H, Ahmed T, Compans RW, Wang BZ.

Biomed Res Int. 2013;2013:686549. doi: 10.1155/2013/686549. Epub 2013 Jul 30.

48.

Gain-of-function experiments on H7N9.

Fouchier RA, Kawaoka Y, Cardona C, Compans RW, García-Sastre A, Govorkova EA, Guan Y, Herfst S, Orenstein WA, Peiris JS, Perez DR, Richt JA, Russell C, Schultz-Cherry SL, Smith DJ, Steel J, Tompkins SM, Topham DJ, Treanor JJ, Tripp RA, Webby RJ, Webster RG.

Science. 2013 Aug 9;341(6146):612-3. doi: 10.1126/science.341.6146.612. No abstract available.

PMID:
23929965
49.

Avian flu: Gain-of-function experiments on H7N9.

Fouchier RA, Kawaoka Y, Cardona C, Compans RW, Fouchier RA, García-Sastre A, Govorkova EA, Guan Y, Herfst S, Kawaoka Y, Orenstein WA, Peiris JS, Perez DR, Richt JA, Russell C, Schultz-Cherry SL, Smith DJ, Steel J, Tompkins SM, Topham DJ, Treanor JJ, Tripp RA, Webby RJ, Webster RG.

Nature. 2013 Aug 8;500(7461):150-1. doi: 10.1038/500150a. No abstract available.

PMID:
23925229
50.

Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch.

Quan FS, Kim YC, Song JM, Hwang HS, Compans RW, Prausnitz MR, Kang SM.

Clin Vaccine Immunol. 2013 Sep;20(9):1433-9. doi: 10.1128/CVI.00251-13. Epub 2013 Jul 17.

Supplemental Content

Loading ...
Support Center